½ÃÀ庸°í¼­
»óǰÄÚµå
1620750

ÇÁ¸®½ÃÀü ¸Þµð½Å ½ÃÀå : ±â¼ú, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, ¹èÆ÷º° - ¼¼°è ¿¹Ãø(2025-2030³â)

Precision Medicine Market by Technology (Big Data Analytics, Bioinformatics, Companion Diagnostics), Application (CNS, Immunology, Oncology), End-User, Deployment - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 193 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÇÁ¸®½ÃÀü ¸Þµð½Å ½ÃÀåÀº 2023³â¿¡ 681¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 757¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 11.22%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1,434¾ï 3,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¤¹ÐÀÇÇÐÀº À¯ÀüÇÐ, ȯ°æÀû Ãø¸é, »ýȰ½À°ü µîÀÇ ¿äÀÎÀ» °í·ÁÇÏ¿© ȯÀÚ °³°³ÀÎÀÇ Æ¯¼º¿¡ ¸Â´Â Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ Á¢±Ù ¹æ½ÄÀº º¸´Ù °³ÀÎÈ­µÇ°í È¿°úÀûÀÎ ÀÇ·á ¼Ö·ç¼ÇÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ÀÇ·á ÇàÀ§¸¦ À籸¼ºÇϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·áÀÇ Çʿ伺Àº ȯÀÚ °á°ú¸¦ °³¼±Çϰí ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» ¹ÙÅÁÀ¸·Î ¾Ï, ½ÉÇ÷°ü Áúȯ, À¯Àü¼º Áúȯ µî Áúº´ °ü¸®¿¡¼­ °³ÀÎ ¸ÂÃãÇü Ä¡·á °èȹ¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·áÀÇ Àû¿ë ¹üÀ§´Â À¯ÀüüÇÐ, µðÁöÅÐ Çコ ±â¼ú, ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®¿¡ À̸£±â±îÁö ´Ù¾çÇϸç, ÀǾàǰ °³¹ß, Áúº´ Á¶±â ¹ß°ß, Ä¡·á¹ý ¼±Åÿ¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÃÖÁ¾ »ç¿ë ¹üÀ§´Â ±¤¹üÀ§ÇÏ¸ç ¹ÙÀÌ¿À Á¦¾à, Áø´Ü ȸ»ç, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü µî ´Ù¾çÇÑ ºÐ¾ß¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¼ºÀå ¿äÀÎÀ¸·Î´Â À¯ÀüüÇÐÀÇ ¹ßÀü, R&D ÅõÀÚ Áõ°¡, Ç¥ÀûÄ¡·á¿¡ ´ëÇÑ °ü½É Áõ°¡ µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤ºÎÀÇ Áö¿ø°ú »ý¸í°øÇÐ ±â¾÷°ú ÇаèÀÇ Çù·ÂÀ¸·Î ½ÃÀå È®´ë°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ´Â AI¸¦ Ȱ¿ëÇÑ À¯Àüü ºÐ¼®°ú ¿¹Ãø °á°ú¸¦ °­È­Çϱâ À§ÇÑ ºòµ¥ÀÌÅÍ ÅëÇÕ¿¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Àâ±â À§Çؼ­´Â µ¥ÀÌÅÍ ºÐ¼®¿¡ ´ëÇÑ ÅõÀÚ¿Í Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» À§ÇÑ ÆÄÆ®³Ê½Ê ±¸ÃàÀÌ Áß¿äÇÕ´Ï´Ù. ±×·¯³ª ³ôÀº °³¹ß ºñ¿ë, µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¿ì·Á, ±ÔÁ¦ À庮 µî ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿ä¼Òµµ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·áÁø°ú ȯÀÚµéÀÇ Àνİú ¼ö¿ëÀÌ Á¦ÇÑÀûÀ̶ó´Â Á¡µµ Å« À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Çõ½Å¿¡ °¡Àå ÀûÇÕÇÑ ºÐ¾ß´Â ºñ¿ë È¿À²ÀûÀÎ À¯Àüü ±â¼ú °³¹ß°ú Á¤¹Ð Áø´ÜÀÇ ¹ßÀüÀÔ´Ï´Ù. ȯÀÚ Á¢±Ù¼º°ú Âü¿©¸¦ ÃËÁøÇÏ´Â »õ·Î¿î ºñÁî´Ï½º ¸ðµ¨À» ¸ð»öÇÏ¸é ´õ ¸¹Àº ¼ºÀåÀ» ±â´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀº º»ÁúÀûÀ¸·Î ¿ªµ¿ÀûÀ̸ç, ºü¸¥ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ÀÌÇØ°ü°èÀÚµéÀÇ ¹Îø¼º°ú ¼±°ßÁö¸íÀÌ ÇÊ¿äÇÕ´Ï´Ù. ±â¾÷µéÀº °³ÀÎÈ­µÈ ÇコÄɾîÀÇ ¹Ì¹¦ÇÑ ¼ö¿ä¿¡ ´ëÀÀÇÏ°í °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ Ã·´Ü ±â¼úÀ» ÅëÇÕÇϰí È®Àå °¡´ÉÇÑ ¼Ö·ç¼ÇÀ» ¸¸µå´Â µ¥ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 681¾ï 2,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 757¾ï ´Þ·¯
¿¹Ãø³â(2030) 1,434¾ï 3,000¸¸ ´Þ·¯
CAGR(%) 11.22%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Á¤¹ÐÀÇ·á ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³ÇÑ´Ù.

Á¤¹ÐÀÇÇÐ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Á¤ºÎ ÀÚ±Ý Áõ°¡¿Í ¿Â¶óÀÎ °øµ¿ Æ÷·³ Áõ°¡
    • Á¤¹ÐÀÇ·á ºÐ¾ß¿¡¼­ ÀΰøÁö´É Ȱ¿ë Áõ°¡
    • ½ºÅ¸Æ®¾÷ÀÇ È°¹ßÇÑ ÁøÀÔÀ¸·Î ¾Ï »ý¹°ÇÐÀÇ ¹ßÀü
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Á¤¹ÐÀÇÇÐ ±â¹Ý Ä¡·áÀÇ ±Þ¿©È­ ºÎÁ·
  • ½ÃÀå ±âȸ
    • Á¤¹ÐÀÇ·á ºÐ¾ß Å¬¶ó¿ìµå ±â¹Ý ¼Ö·ç¼Ç µµÀÔ È®´ë
    • À¯ÀüÀÚÀÇ Æ¯Â¡À» ¹àÈ÷±â À§ÇÑ Á¦¾àȸ»ç¿Í ¼ÒÇÁÆ®¿þ¾î ȸ»çÀÇ Àü·«Àû Á¦ÈÞ
  • ½ÃÀå °úÁ¦
    • º¹ÀâÇÑ FDA ¾à¼öó¸® ½ÂÀηü

Porter's Five Forces: Á¤¹ÐÀÇ·á ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Á¤¹ÐÀÇ·á ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

PESTLE ºÐ¼® : Á¤¹ÐÀÇ·á ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Á¤¹ÐÀÇÇÐ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Á¤¹ÐÀÇÇÐ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

Á¤¹ÐÀÇÇÐ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Á¤¹ÐÀÇÇÐ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Á¤¹ÐÀÇ·á ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î º¥´õ¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¤¹ÐÀÇÇÐ ½ÃÀå¿¡¼­ÀÇ ¼º°øÀ» À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ Á¤¹ÐÀÇÇÐ ½ÃÀå¿¡¼­ÀÇ ¼º°ø °æ·Î¸¦ Á¦½ÃÇÕ´Ï´Ù.

Á¤¹ÐÀÇ·á ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ ±â¾÷Àº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
    • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
      • Á¤Ä¡Àû
      • °æÁ¦Àû
      • »çȸÀû
      • ±â¼úÀû
      • ¹ýÀû
      • ȯ°æÀû

    Á¦6Àå ÇÁ¸®½ÃÀü ¸Þµð½Å ½ÃÀå : ±â¼úº°

    • ºòµ¥ÀÌÅÍ ºÐ¼®
    • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º
    • µ¿¹ÝÁø´Ü
    • â¾à
    • À¯ÀüÀÚ ¼­¿­ ºÐ¼®

    Á¦7Àå ÇÁ¸®½ÃÀü ¸Þµð½Å ½ÃÀå : ¿ëµµº°

    • ÁßÃ߽Űæ°è
    • ¸é¿ªÇÐ
    • Á¾¾çÇÐ
    • È£Èí±â

    Á¦8Àå ÇÁ¸®½ÃÀü ¸Þµð½Å ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

    • »ý¸í°øÇÐ ¹× Áø´Ü±â¾÷
    • ¿¬±¸¼Ò¡¤Á¦¾à
    • ¿¬±¸¼¾ÅÍ ¹× Á¤ºÎ±â°ü

    Á¦9Àå ÇÁ¸®½ÃÀü ¸Þµð½Å ½ÃÀå : Àü°³º°

    • Ŭ¶ó¿ìµå»ó
    • ¿ÂÇÁ·¹¹Ì½º

    Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ÇÁ¸®½ÃÀü ¸Þµð½Å ½ÃÀå

    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
    • ¹Ì±¹

    Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇÁ¸®½ÃÀü ¸Þµð½Å ½ÃÀå

    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • Àεµ³×½Ã¾Æ
    • ÀϺ»
    • ¸»·¹À̽þÆ
    • Çʸ®ÇÉ
    • ½Ì°¡Æ÷¸£
    • Çѱ¹
    • ´ë¸¸
    • ű¹
    • º£Æ®³²

    Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÇÁ¸®½ÃÀü ¸Þµð½Å ½ÃÀå

    • µ§¸¶Å©
    • ÀÌÁýÆ®
    • Çɶõµå
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • À̽º¶ó¿¤
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ³ªÀÌÁö¸®¾Æ
    • ³ë¸£¿þÀÌ
    • Æú¶õµå
    • īŸ¸£
    • ·¯½Ã¾Æ
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ½ºÀ§½º
    • ÅÍŰ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ¿µ±¹

    Á¦13Àå °æÀï ±¸µµ

    • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
    • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
    • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Àü·« ºÐ¼®°ú Á¦¾È

    ±â¾÷ ¸ñ·Ï

    • AccessDX Holdings
    • Adaptive Biotechnologies Corporation
    • Biocrates Life Sciences AG
    • bioMerieux SA
    • Caris Life Sciences
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche AG
    • Foundation Medicine, Inc.
    • Guardant Health, Inc.
    • healthOme
    • Illumina, Inc.
    • Intomics by ZS Associates, Inc.
    • Invitae Corporation.
    • Laboratory Corporation of America Holdings
    • Medtronic PLC
    • Natera Inc.
    • Novartis AG
    • Pfizer Inc.
    • Precision Medicine Group, LLC
    • QIAGEN GmbH
    • Quest Diagnostics Incorporated
    • Strata Oncology, Inc.
    • Syapse, Inc.
    • Tempus Labs, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Thermo Fisher Scientific Inc.
    BJH 25.01.08

    The Precision Medicine Market was valued at USD 68.12 billion in 2023, expected to reach USD 75.70 billion in 2024, and is projected to grow at a CAGR of 11.22%, to USD 143.43 billion by 2030.

    Precision medicine involves tailoring medical treatment to the individual characteristics of each patient, considering factors like genetics, environmental aspects, and lifestyle. This approach is reshaping medical practices by allowing more personalized and effective healthcare solutions. The necessity for precision medicine is underscored by its potential to improve patient outcomes and reduce healthcare costs, catering to the heightened need for personalized treatment plans in managing diseases like cancer, cardiovascular conditions, and genetic disorders. In terms of application, precision medicine spans genomics, digital health technologies, and biomarker analysis, making it pivotal in drug development, early detection of diseases, and therapy selection. The end-use scope is broad, affecting sectors such as biopharmaceuticals, diagnostic companies, and healthcare providers. Influencing growth factors include advancements in genomics, increased R&D investments, and a growing emphasis on targeted therapies. Moreover, governmental support, combined with collaborations between biotech firms and academic institutions, is driving market expansion. Emerging opportunities lie in AI-driven genomic analytics and the integration of big data to enhance predictive outcomes. For businesses aiming to seize these opportunities, investing in data analytics and forging partnerships for innovative solutions will be critical. However, there are challenges like high costs of development, data privacy concerns, and regulatory hurdles that could impede growth. Limited awareness and acceptance among healthcare providers and patients also pose significant barriers. The best areas for innovation include developing cost-effective genomic technologies and advancing precision diagnostics. Exploring new business models that promote patient accessibility and engagement can unlock additional growth. The market is inherently dynamic, with rapid technological advancements necessitating agility and foresight from stakeholders. Businesses should focus on integrating cutting-edge technologies and creating scalable solutions to remain competitive while addressing the nuanced demands of personalized healthcare.

    KEY MARKET STATISTICS
    Base Year [2023] USD 68.12 billion
    Estimated Year [2024] USD 75.70 billion
    Forecast Year [2030] USD 143.43 billion
    CAGR (%) 11.22%

    Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Precision Medicine Market

    The Precision Medicine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

    • Market Drivers
      • Rising government funding and rising online collaborative forums
      • Increasing use of artificial intelligence in precision medicine
      • Advancement in cancer biology complemented by the active presence of startups
    • Market Restraints
      • Lack of reimbursement for precision medicine-based treatment
    • Market Opportunities
      • Growing adoption of cloud-based solutions in precision medicine
      • Strategic alliances among pharmaceutical and software companies to characterize the genes
    • Market Challenges
      • Complicated FDA pharmacotherapy approval rate

    Porter's Five Forces: A Strategic Tool for Navigating the Precision Medicine Market

    Porter's five forces framework is a critical tool for understanding the competitive landscape of the Precision Medicine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

    PESTLE Analysis: Navigating External Influences in the Precision Medicine Market

    External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Precision Medicine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

    Market Share Analysis: Understanding the Competitive Landscape in the Precision Medicine Market

    A detailed market share analysis in the Precision Medicine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

    FPNV Positioning Matrix: Evaluating Vendors' Performance in the Precision Medicine Market

    The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Precision Medicine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

    Strategy Analysis & Recommendation: Charting a Path to Success in the Precision Medicine Market

    A strategic analysis of the Precision Medicine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

    Key Company Profiles

    The report delves into recent significant developments in the Precision Medicine Market, highlighting leading vendors and their innovative profiles. These include AccessDX Holdings, Adaptive Biotechnologies Corporation, Biocrates Life Sciences AG, bioMerieux SA, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Foundation Medicine, Inc., Guardant Health, Inc., healthOme, Illumina, Inc., Intomics by ZS Associates, Inc., Invitae Corporation., Laboratory Corporation of America Holdings, Medtronic PLC, Natera Inc., Novartis AG, Pfizer Inc., Precision Medicine Group, LLC, QIAGEN GmbH, Quest Diagnostics Incorporated, Strata Oncology, Inc., Syapse, Inc., Tempus Labs, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific Inc..

    Market Segmentation & Coverage

    This research report categorizes the Precision Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

    • Based on Technology, market is studied across Big Data Analytics, Bioinformatics, Companion Diagnostics, Drug Discovery, and Gene Sequencing.
    • Based on Application, market is studied across CNS, Immunology, Oncology, and Respiratory.
    • Based on End-User, market is studied across Biotechnology & Diagnostic Companies, Laboratories & Pharmaceuticals, and Research Centers & Government Institutions.
    • Based on Deployment, market is studied across On-Cloud and On-Premise.
    • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

    The report offers a comprehensive analysis of the market, covering key focus areas:

    1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

    2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

    3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

    4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

    5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

    The report also answers critical questions to aid stakeholders in making informed decisions:

    1. What is the current market size, and what is the forecasted growth?

    2. Which products, segments, and regions offer the best investment opportunities?

    3. What are the key technology trends and regulatory influences shaping the market?

    4. How do leading vendors rank in terms of market share and competitive positioning?

    5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

    Table of Contents

    1. Preface

    • 1.1. Objectives of the Study
    • 1.2. Market Segmentation & Coverage
    • 1.3. Years Considered for the Study
    • 1.4. Currency & Pricing
    • 1.5. Language
    • 1.6. Stakeholders

    2. Research Methodology

    • 2.1. Define: Research Objective
    • 2.2. Determine: Research Design
    • 2.3. Prepare: Research Instrument
    • 2.4. Collect: Data Source
    • 2.5. Analyze: Data Interpretation
    • 2.6. Formulate: Data Verification
    • 2.7. Publish: Research Report
    • 2.8. Repeat: Report Update

    3. Executive Summary

    4. Market Overview

    5. Market Insights

    • 5.1. Market Dynamics
      • 5.1.1. Drivers
        • 5.1.1.1. Rising government funding and rising online collaborative forums
        • 5.1.1.2. Increasing use of artificial intelligence in precision medicine
        • 5.1.1.3. Advancement in cancer biology complemented by the active presence of startups
      • 5.1.2. Restraints
        • 5.1.2.1. Lack of reimbursement for precision medicine-based treatment
      • 5.1.3. Opportunities
        • 5.1.3.1. Growing adoption of cloud-based solutions in precision medicine
        • 5.1.3.2. Strategic alliances among pharmaceutical and software companies to characterize the genes
      • 5.1.4. Challenges
        • 5.1.4.1. Complicated FDA pharmacotherapy approval rate
    • 5.2. Market Segmentation Analysis
      • 5.2.1. Technology: Big data analytics is advancing the field of precision medicine
      • 5.2.2. Application: Personalized cancer and oncology care using precision medicine
      • 5.2.3. End-user: Efforts by biotechnology and diagnostic companies to invest in R&D and advance the field of precision medicine
      • 5.2.4. Deployment: Integration of AI and cloud solutions to improve efficacy and speed of development of precision medicine services
    • 5.3. Porter's Five Forces Analysis
      • 5.3.1. Threat of New Entrants
      • 5.3.2. Threat of Substitutes
      • 5.3.3. Bargaining Power of Customers
      • 5.3.4. Bargaining Power of Suppliers
      • 5.3.5. Industry Rivalry
    • 5.4. PESTLE Analysis
      • 5.4.1. Political
      • 5.4.2. Economic
      • 5.4.3. Social
      • 5.4.4. Technological
      • 5.4.5. Legal
      • 5.4.6. Environmental

    6. Precision Medicine Market, by Technology

    • 6.1. Introduction
    • 6.2. Big Data Analytics
    • 6.3. Bioinformatics
    • 6.4. Companion Diagnostics
    • 6.5. Drug Discovery
    • 6.6. Gene Sequencing

    7. Precision Medicine Market, by Application

    • 7.1. Introduction
    • 7.2. CNS
    • 7.3. Immunology
    • 7.4. Oncology
    • 7.5. Respiratory

    8. Precision Medicine Market, by End-User

    • 8.1. Introduction
    • 8.2. Biotechnology & Diagnostic Companies
    • 8.3. Laboratories & Pharmaceuticals
    • 8.4. Research Centers & Government Institutions

    9. Precision Medicine Market, by Deployment

    • 9.1. Introduction
    • 9.2. On-Cloud
    • 9.3. On-Premise

    10. Americas Precision Medicine Market

    • 10.1. Introduction
    • 10.2. Argentina
    • 10.3. Brazil
    • 10.4. Canada
    • 10.5. Mexico
    • 10.6. United States

    11. Asia-Pacific Precision Medicine Market

    • 11.1. Introduction
    • 11.2. Australia
    • 11.3. China
    • 11.4. India
    • 11.5. Indonesia
    • 11.6. Japan
    • 11.7. Malaysia
    • 11.8. Philippines
    • 11.9. Singapore
    • 11.10. South Korea
    • 11.11. Taiwan
    • 11.12. Thailand
    • 11.13. Vietnam

    12. Europe, Middle East & Africa Precision Medicine Market

    • 12.1. Introduction
    • 12.2. Denmark
    • 12.3. Egypt
    • 12.4. Finland
    • 12.5. France
    • 12.6. Germany
    • 12.7. Israel
    • 12.8. Italy
    • 12.9. Netherlands
    • 12.10. Nigeria
    • 12.11. Norway
    • 12.12. Poland
    • 12.13. Qatar
    • 12.14. Russia
    • 12.15. Saudi Arabia
    • 12.16. South Africa
    • 12.17. Spain
    • 12.18. Sweden
    • 12.19. Switzerland
    • 12.20. Turkey
    • 12.21. United Arab Emirates
    • 12.22. United Kingdom

    13. Competitive Landscape

    • 13.1. Market Share Analysis, 2023
    • 13.2. FPNV Positioning Matrix, 2023
    • 13.3. Competitive Scenario Analysis
      • 13.3.1. Thirona Raises EUR 7.5 Million New Financing to Accelerate the Adoption of its Breakthrough Innovations for Precision Medicine
      • 13.3.2. Novartis completes acquisition of precision medicine developer Chinook
      • 13.3.3. New Dartmouth Center Applies AI to Improve Health Outcomes
    • 13.4. Strategy Analysis & Recommendation

    Companies Mentioned

    • 1. AccessDX Holdings
    • 2. Adaptive Biotechnologies Corporation
    • 3. Biocrates Life Sciences AG
    • 4. bioMerieux SA
    • 5. Caris Life Sciences
    • 6. Exact Sciences Corporation
    • 7. F. Hoffmann-La Roche AG
    • 8. Foundation Medicine, Inc.
    • 9. Guardant Health, Inc.
    • 10. healthOme
    • 11. Illumina, Inc.
    • 12. Intomics by ZS Associates, Inc.
    • 13. Invitae Corporation.
    • 14. Laboratory Corporation of America Holdings
    • 15. Medtronic PLC
    • 16. Natera Inc.
    • 17. Novartis AG
    • 18. Pfizer Inc.
    • 19. Precision Medicine Group, LLC
    • 20. QIAGEN GmbH
    • 21. Quest Diagnostics Incorporated
    • 22. Strata Oncology, Inc.
    • 23. Syapse, Inc.
    • 24. Tempus Labs, Inc.
    • 25. Teva Pharmaceutical Industries Ltd.
    • 26. Thermo Fisher Scientific Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦